- ‘We’re moving quickly’: Startup bags rare disease drug as Thiel-backed CEO eyes $50M fundraiseA rare disease startup with a mission to repurpose proven drugs has licensed a Chinese formulation of a well-known medicine and set its sights on a $50 million fundraise.Fierce Biotech · 5d ago↗ source
- STAT+: Rare disease drugmakers try to avoid Trump price cutsPlus, GOP voters want a crackdown on health care fraud, and how PBMs are skirting state laws.STAT · 5d ago↗ source
- Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesityWith PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.